Healthcare, Pharma & Life Sciences

Memorial Healthcare System Names Madison Workman CEO of Pembroke Hospital

Image
Memorial Healthcare System Names Madison Workman CEO of Pembroke Hospital

Hollywood, Fla. – October 01, 2026 -- Memorial Healthcare System has appointed Madison Workman, FACHE, as chief executive officer of Memorial Hospital Pembroke, a 301-bed facility in Pembroke Pines, placing him in charge of operations and growth strategy at the hospital.

Workman Previously Oversaw $100 Million in Capital Projects at Broward Health North

Workman joins from Broward Health North, a 409-bed Level II trauma hospital, where he served as chief operating officer managing roughly 800 employees across clinical and support services. He expanded his role to lead the systemwide Safety and Security program and the COO Council, while helping direct more than $100 million in construction and capital investment focused on patient throughput and hospital expansion.

Sound Physicians Names Sergio Zanotti CEO of Critical Care Unit

Image
Sound Physicians Names Sergio Zanotti CEO of Critical Care Unit

Nashville – October 01, 2026 -- Sound Physicians has appointed Sergio Zanotti, MD, FCCM, as Chief Executive Officer of its Critical Care specialty, placing him in charge of programs that treat more than 170,000 critically ill patients annually.

Zanotti takes over strategy for a specialty treating 170,000 ICU patients per year

In the role, Dr. Zanotti will oversee operations for Sound Critical Care, working with regional and specialty leadership as well as hospital and health system partners nationwide to implement evidence-based clinical programs. He will also continue supporting physician leadership development across Sound's other clinical specialties.

Codoxo Named to TIME's World's Top HealthTech Companies 2026 List

Image
Codoxo Named to TIME's World's Top HealthTech Companies 2026 List

Duluth, Ga. – October 01, 2026 -- Codoxo has been named to the second edition of TIME's World's Top HealthTech Companies 2026 list, a ranking produced with Statista Inc. that evaluated thousands of health-tech firms before selecting the top 500.

TIME and Statista screened companies on financial performance, reputation and online engagement

The list was announced on September 17, 2026, and is published on Time.com. Companies were assessed using three primary data sources: Financial Performance Metrics, Reputation Analysis, and Online Engagement.

Lakewood-Amedex CEO to Present Bisphosphocin Data at Three Investor Events

Image
Lakewood-Amedex CEO to Present Bisphosphocin Data at Three Investor Events

Sarasota, Fla. – October 01, 2026 -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) will send CEO Kelvin Cooper, Ph.D., to three separate industry conferences this month, placing the clinical-stage antimicrobial developer in front of both investors and infectious-disease specialists within an eight-day window.

CEO to address investor audiences at two New York events in mid-October

Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City, followed by a presentation at the ThinkEquity Conference on October 15, 2026, also in New York City. Both appearances target biotechnology investors evaluating the company's pipeline.

Guardian System Cuts ECMO Pressure Injuries 36.2% in New Study

Image
Guardian System Cuts ECMO Pressure Injuries 36.2% in New Study

Palo Alto, Calif. – October 01, 2026 -- TurnCare, Inc. reported a 36.2% reduction in total hospital-acquired pressure injuries (HAPIs) among ECMO patients following implementation of its GuardianTM System, according to new clinical data presented at the 37th Annual Extracorporeal Life Support Organization (ELSO) 2026 Conference in Nashville, Tennessee.

Single-center study tracks outcomes across 2,707 ECMO days

The retrospective pre- and post-cohort analysis, conducted at M Health Fairview University of Minnesota Medical Center, compared a baseline group of 317 ECMO patients (327 runs, 2,112 ECMO days) against a Guardian-treated cohort of 92 patients (97 runs, 595 ECMO days). Chris Linke, MHI, RN, CSSMBB, presented the findings.

HoneyNaps Gains CRO Status, Expands AI Sleep Data Services for Pharma

Image
HoneyNaps Gains CRO Status, Expands AI Sleep Data Services for Pharma

Boston – October 01, 2026 -- HoneyNaps, an AI-based sleep health technology company, has completed registration as a clinical research organization (CRO) with South Korea's National Enterprise for Clinical Trials (KoNECT), broadening its role in pharmaceutical and medical device trials worldwide.

HoneyNaps secures CRO registration with KoNECT, expanding multicenter trial capacity

The company has supported clinical trials involving more than 10,000 participants and can now operate multicenter, multidisciplinary studies under its new CRO status. The registration formalizes HoneyNaps' position as a provider of standardized sleep data analysis for pharmaceutical companies, medical device developers, and research organizations.

Lutris Pharma's LUT014 Gel Hits 71.8% Success Rate in Phase 2 Rash Trial

Image
Lutris Pharma's LUT014 Gel Hits 71.8% Success Rate in Phase 2 Rash Trial

Tel Aviv, Israel – October 01, 2026 -- Lutris Pharma reported that its topical B-Raf inhibitor LUT014 achieved Treatment Success in 71.8% of patients with EGFR inhibitor-induced acneiform rash, compared with 38.5% on placebo (p=0.003), in updated Phase 2 data presented at the 35th EADV Congress in Vienna.

LUT014 0.1% gel cuts clinician-assessed rash severity and patient symptom burden

Among the composite endpoint's components, 56.4% of patients on LUT014 0.1% achieved at least a one-grade improvement on the CTCAE v5.0 acneiform rash scale versus 15.4% on placebo (p=0.0002). Using the FACT-EGFRI-18 patient-reported symptom score, 53.8% of treated patients reported at least a five-point improvement versus 28.2% on placebo (p=0.021).

Brogidirsen Shows 5-Year Motor Function Benefit in DMD Trial

Image
Brogidirsen Shows 5-Year Motor Function Benefit in DMD Trial

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Six-participant trial records no serious adverse events over five years

The data, presented by Japan's National Center of Neurology and Psychiatry (NCNP) at the 31st annual International Congress of the World Muscle Society in Hiroshima, Japan, covered an open-label extension of an investigator-initiated clinical trial. All six participants received weekly intravenous dosing of brogidirsen (NS-089/NCNP-02), an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP. After five years of administration, no serious or severe adverse events, anaphylaxis, or discontinuations tied to long-term dosing were recorded.

Nanoscope's MOGENRY Gains Priority Review in Japan for IRD Patients

Image
Nanoscope's MOGENRY Gains Priority Review in Japan for IRD Patients

Dallas – October 01, 2026 -- Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted and granted priority review to Nanoscope Therapeutics' New Drug Application for MOGENRY (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy for inherited retinal dystrophies (IRDs). If approved by the Ministry of Health, Labour and Welfare, MOGENRY would become the first disease-agnostic treatment available to IRD patients in Japan, a condition caused by mutations across more than 250 genes that leads to progressive photoreceptor loss and blindness.